NeurogesX ( NGSX) Drug/indication: Qutenza for HIV-associated peripheral neuropathy FDA advisory panel: Feb. 9, 2012 Approval decision date: March 7, 2012 Teva ( TEVA) and BioSante Pharmaceuticals ( BPAX) Drug/indication: Bio-T-Gel for hypogonadism Approval decision date: Feb. 14, 2012 Bio-T-Gel is a once-daily gel used to treat low testosterone in men. Corcept Pharmaceuticals ( CORT) Drug/indication: Corlux for Cushing's Syndrome. Approval decision date: Feb. 17, 2012 FDA will not convene an advisory panel to review Corlux. Chelsea Therapeutics ( CHTP) Drug/indication: Northera for orthostatic hypotension FDA advisory panel: Feb. 23, 2012 (tentative) Approval decision date: March 28, 2012 Vivus ( VVUS), Arena Pharmaceuticals ( ARNA) and Orexigen Therapeutics ( VVUS) Drugs/indication: Qnexa, lorcaserin and Contrave for obesity. FDA advisory panel: The Endocrinologic and Metabolic Drugs Advisory Committee has tentative meetings scheduled for Feb. 22 and March 28-29, 2012. FDA held advisory panels to review all three of these controversial weight-loss drugs in 2010. FDA subsequently rejected all three drugs. In 2012, Vivus and its obesity drug competitors are back for another shot, and FDA will once again bring together a group of outside experts to weigh the pros and cons of treating obesity with a pill. Discovery Labs ( DSCO) Drug/indication: Surfaxin for respiratory distress syndrome in premature infants. Approval decision date: March 6, 2012 This is Discovery's fifth attempt at convincing FDA to approve Surfaxin. Roche ( RHHBY) and Curis ( CRIS) Drug/indication: Vismodegib for advanced basal cell carcinoma. Approval decision date: March 8, 2012. MAP Pharmaceuticals ( MAPP) Drug/indication: Levadex for migraines Approval decision date: March 26, 2012 Levadex is an inhaled migraine drug. FDA has not yet announced whether it intends to hold an advisory panel to review Levadex. Affymax ( AFFY) Drug/indication:peginesatide for anemia in kidney dialysis patients. Approval decision date:March 27, 2012 Peginesatide, injected once monthly, aims to compete against Amgen's ( AMGN) Epogen ($2.5 billion in 2010 sales) as a treatment for anemia in patients with chronic kidney disease, although peginesatide use would be limited to sicker kidney dialysis patients only. On Dec. 7, an FDA advisory panel voted 15-1 to recommend peginesatide's approval. Vivus ( VVUS) Drug/indication: Qnexa for obesity Approval decision date: April 17, 2012 FDA rejected Qnexa initially in 2010 due to safety concerns.